Oracle (ORCL): Growth Inflection Pushed Out Until F18 - Cowen
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Cowen analyst, Derrick Wood, reiterated his Outperform rating on shares of Oracle (NYSE: ORCL) but recognized that there are several new factors pressuring EPS. Software growth was solid and came in at the high-end of guidance & GM expansion elements are well intact; but the combination of weakening hardware and transitory factors below the operating line (higher tax rates, new debt burden w/o N closure) are spoiling the EPS growth recovery.
Confidence in cloud traction remains high & EPS growth is expected to continue in FY17, but an inflection is not likely to happen till FY18. No change to the price target of $46 which represents a ~16x P/E multiple.
Shares of Oracle closed at $40.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM (IBM): Closer Look Shows The - Jefferies
- Union Pacific (UNP) PT Raised to $120 at Aegis Capital Following Solid 4Q
- Checkpoint Software (CHKP) PT Raised to $94 at Stifel Following 4Q Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Earnings
Related EntitiesCowen & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!